CIBC World Market
APLS

CIBC World Market’s Apellis Pharmaceuticals APLS Stock Holding History

CIBC World Market’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-4,340
Closed -$260K – 1290
2023
Q4 		$260K Buy
+4,340
New +$220K ﹤0.01% 1103

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

CIBC World Market's APLS Position: Q1 2024 in Review

CIBC World Market sold out of Apellis Pharmaceuticals (APLS) in Q1 2024, closing a stake of 4,340 shares — an estimated $260K sold.

CIBC World Market first reported a position in APLS in Q4 2023 and held it in 1 quarter. The position peaked at $260K in Q4 2023. 302 funds tracked by Wall St. Rank hold APLS as of Q1 2024.

  • CIBC World Market reported no remaining Apellis Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • CIBC World Market sold 4,340 Apellis Pharmaceuticals shares in Q1 2024, an estimated $260K.
  • CIBC World Market first reported a position in Apellis Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • CIBC World Market's Apellis Pharmaceuticals position peaked at $260K in Q4 2023.
  • 302 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2024.

Based on CIBC World Market's 13F filing for Q1 2024, filed 13 May 2024.